Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 10/20 | 0.47 |
| ▸ | BACE1 | P56817 | 10/20 | 0.47 |
| ▸ | BCHE | P06276 | 8/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.44 |
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4542372 | 0.88 | ACHE (0.56) | ACHEBACE1BCHEMEN1KMT2A | |
| SCHEMBL17606641 | 0.86 | ACHE (0.50) | ACHEBACE1BCHEMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL9717982 | 0.85 | ACHE (0.49) | ACHEBACE1BCHEMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL9178350 | 0.85 | ACHE (0.49) | ACHEBACE1BCHEMEN1KMT2A | |
| SCHEMBL15544628 | 0.74 | ACHE (0.49) | ACHEBACE1BCHEMEN1KMT2A | |
| SCHEMBL9230559 | 0.73 | POLB (0.50) | ACHEBACE1BCHEMEN1KMT2A | |
| SCHEMBL6213916 | 0.71 | OPRL1 (0.59) | ACHEMEN1KMT2AOPRL1POLB | |
| SCHEMBL9717983 | 0.70 | ACHE (0.44) | ACHEBACE1BCHEMEN1KMT2A | |
| SCHEMBL17325170 | 0.70 | OPRL1 (0.58) | MEN1KMT2AOPRL1POLBCCR3 | |
| SCHEMBL19322400 | 0.69 | OPRL1 (0.53) | KMT2AOPRL1POLBCCR3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2637660-A1 | FATTY ACID SYNTHASE INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2013-09-18 | — | — | EP | disclosed |
| US-20130237535-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-09-12 | — | — | US | disclosed |
| WO-2012064642-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237535-A1 | FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | ACHE 4549/4885BACE1 2456/4885BCHE 3491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.